ERCC1在晚期非小细胞肺癌中的表达及其与预后的相关性

Expression and prognostic significance of ERCC1 in advanced non-small cell lung cancer

目的:探讨核苷酸切除修复交叉互补基因1(ERCC1)在晚期非小细胞肺癌中的表达及预后意义。方法:采用免疫组化S-P法检测78例Ⅲ、Ⅳ期非小细胞肺癌患者中核苷酸切除修复交叉互补基因1(ERCC1)的表达情况,采用χ2检验、Kaplan-Meier生存曲线和COX多因素回归分析,分析与ERCC1表达相关的因素及其对生存期的影响。结果:78例患者ERCC1的阳性表达率为47.44%(37/78),与患者性别、年龄、病理类型、癌细胞分化程度、淋巴结转移、TNM分期以及肿瘤大小均无关;ERCC1阳性组中位生存期为14个月,ERCC1阴性组中位生存期为9个月,两组比较差异有统计学意义(P=0.0477);COX多因素回归分析示ERCC1表达状态是影响本组患者预后的独立因素。结论:晚期非小细胞肺癌存在ERCC1的表达,ERCC1表达阳性者中位生存期长于ERCC1表达阴性者。ERCC1蛋白检测对患者的预后判断有一定指导意义。

Objective：To explore the expression and clinical prognostic significance of ERCC1 in advanced non-small cell lung cancer（NSCLC）.Methods：The expression of ERCC1 was examined by immunohistochemical technique in 78 patients with advanced non-small-cell lung cancer.Expression differences of ERCC1 and its relationship with the patients＇ median survival were analyzed with χ2 test,Kaplan-Meier survival curve and COX multivariate regression.Results：The expression of ERCC1 was 47.44% among 78 cases,and there was no correlation with patient age,sex,pathology type,the degree of the cancer,lymph node metastasis,clinical stage and tumor size;the median survival of the ERCC1 positive group was higher than the ERCC1 negative group（P=0.0477）;COX multivariate regression analysis showed that ERCC1 expression was an independent prognostic factor for NSCLC.Conclusion：In advanced non-small cell lung cancer there is the expression of ERCC1.The patients with positive ERCC1 expression had significant longer survival time than those with negative ERCC1 expression.ERCC1 protein detection may help to guide the prognosis judgment.